TrialHIV medicine2023

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.

Franco Maggiolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.